CATX
AMEX · Biotechnology
Perspective Therapeutics Inc
$3.85
-0.05 (-1.28%)
Open$3.87
Previous Close$3.90
Day High$3.98
Day Low$3.83
52W High$6.16
52W Low$1.96
Volume—
Avg Volume1.87M
Market Cap410.46M
P/E Ratio—
EPS$-1.39
SectorBiotechnology
Analyst Ratings
Strong Buy
20 analysts
Price Target
+410.9% upside
Current
$3.85
$3.85
Target
$19.67
$19.67
$12.33
$19.67 avg
$23.14
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.28M | 2.03M | 70.28M |
| Net Income | -148,950,430 | -213,090,743 | -10,926,196 |
| Profit Margin | -11,665.3% | -11,082.0% | -15.6% |
| EBITDA | -157,308,968 | -237,551,294 | -18,107,687 |
| Free Cash Flow | — | — | -6,087,830 |
| Rev Growth | -37.1% | -37.1% | +8.8% |
| Debt/Equity | 0.01 | 0.01 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |